VEGFA and non-small cell lung carcinoma: Several phase 2 and 3 clinical trials demonstrated that the addition of bevacizumab (BEV, a humanized monoclonal antibody against the VEGF-A isoform) to CHT improves the PFS and OS of NSCLC patients [16,17,18,19,20].